Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.43 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387033 | 0.90 | CDK2 (0.50) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6603729 | 0.82 | CDK2 (0.51) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6604728 | 0.82 | CDK2 (0.48) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL4021384 | 0.81 | CDK2 (0.68) | CDK2CDK4CCNA2CCNA1 | |
| SCHEMBL6623217 | 0.81 | CDK2 (0.65) | CDK2CDK4CCNA2CCNA1SYK | |
| SCHEMBL6604316 | 0.80 | CDK2 (0.50) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6443063 | 0.79 | CDK2 (0.58) | CDK2CDK4SYK | |
| SCHEMBL6605982 | 0.79 | CDK2 (0.49) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL6106036 | 0.78 | CDK2 (0.64) | CDK2CDK4CCNA2CCNA1POLB | |
| SCHEMBL5098992 | 0.77 | CDK2 (0.60) | CDK2CDK4CCNA2CCNA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485375-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | EP | claimed |
| US-20050256311-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1485375-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | claimed |
| WO-2003076435-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | claimed |
| EP-1485375-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-7485638-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | CDK2 24/4885CDK4 48/4885CCNA2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.